ArticleGut pathogens2026
Recurrent Campylobacter jejuni bacteraemia with independent acquisition of carbapenem resistance in three ST9611 isolates: a case series in immunocompromised hosts.
Article in Gut pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCampylobacter jejuni is a leading cause of bacterial gastroenteritis but rarely causes bacteraemia, except in immunocompromised hosts. Carbapenem resistance in C. jejuni remains uncommon, and the clinical evolution of resistance during infection has not been well described.
methodsWe report a case series of three immunocompromised adults with recurrent C. jejuni bacteraemia at a tertiary hospital in Singapore between 2024 and 2025.
resultsAll three patients had underlying haematologic or autoimmune disorders associated with hypogammaglobulinaemia. Each experienced multiple episodes of C. jejuni bacteraemia despite prolonged carbapenem therapy, with isolates showing stepwise increases in meropenem minimum inhibitory concentrations (MICs) from ≤ 0.05 mg/L to as high as 16 mg/L. No abscesses or drainable foci were identified radiologically. Two patients received regular intravenous immunoglobulin (IVIG) replacement after low serum IgG levels were detected. In all cases, recurrences ceased after introduction of eravacycline therapy, with or without concurrent oral gentamicin, in combination with IVIG support. One patient later died of progression of underlying lymphoma.
conclusionsThis series demonstrates the potential for acquired carbapenem resistance to develop in C. jejuni during recurrent bacteraemia in immunocompromised hosts. Eravacycline, alongside immunoglobulin replacement, may represent a viable therapeutic option in such refractory infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.